Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Closed 06-09 16:00:00 EDT

3.43

+0.06

+1.78%

盘后3.43

+0.000.00%

16:26 EDT

High3.54	Low3.31	Vol488.24K
Open3.44	D1 Closing3.37	Amplitude6.88%
Mkt Cap207.23M	Tradable Cap136.41M	Total Shares60.42M
T/O1.67M	T/O Rate1.23%	Tradable Shares39.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.43,"timestamp":1781035200000,"preClose":3.37,"halted":0,"volume":488236,"hourTrading":{"tag":"盘后","latestPrice":3.43,"preClose":3.43,"latestTime":"16:26 EDT","volume":6016,"amount":20634.88,"timestamp":1781036782710,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017804154302670638,"floatShares":39771100,"shares":60416887,"eps":-1.979861,"marketStatus":"Closed","change":0.06,"latestTime":"06-09 16:00:00 EDT","open":3.44,"high":3.54,"low":3.308,"amount":1670349,"amplitude":0.068843,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979861,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781078400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.37,"preHourTrading":{"tag":"盘前","latestPrice":3.44,"preClose":3.37,"latestTime":"09:29 EDT","volume":385,"amount":1333.4799939999998,"timestamp":1781011798411,"change":0.07,"changeRate":0.020772,"amplitude":0.032641},"postHourTrading":{"tag":"盘后","latestPrice":3.43,"preClose":3.43,"latestTime":"16:26 EDT","volume":6016,"amount":20634.88,"timestamp":1781036782710,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.885036,"impliedVol":1.1799,"impliedVolPercentile":0.3944},"requestUrl":"/m/hq/s/VYGR","defaultTab":"news","newsList":[{"id":"2642435726","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435726","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435726?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:30","pubTimestamp":1780939810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-ovid-therapeutics-ovid-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-ovid-therapeutics-ovid-and-establishment-labs-holdings-esta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OVID","BK4585","XBI","BK4139","BK4581","LABU","HCSG","BK4137","BK4588","LU0128526141.USD","LU2324357040.USD","XLV","VYGR","LU0029874061.USD","ESTA","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640300910","title":"Guggenheim Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640300910","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640300910?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:39","pubTimestamp":1780400369,"startTime":"0","endTime":"0","summary":"In a report released today, Debjit Chattopadhyay from Guggenheim maintained a Buy rating on Voyager Therapeutics, with a price target of $22.00. Ac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-its-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640443954","title":"Voyager Therapeutics announces FDA clearance for VY1706 IND application","url":"https://stock-news.laohu8.com/highlight/detail?id=2640443954","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640443954?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:48","pubTimestamp":1780318109,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706, the company’s investig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-fda-clearance-for-vy1706-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-announces-fda-clearance-for-vy1706-ind-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","VYGR","BK4139","IND","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895975","title":"Voyager Therapeutics says FDA clears IND for Alzheimer’s gene therapy VY1706","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895975","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640895975?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:04","pubTimestamp":1780315465,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics won FDA clearance of its IND for VY1706, a tau-silencing gene therapy for Alzheimer’s disease.Dosing in a multi-site, open-label, dose-escalation trial is expected to start in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4WPlY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640995912","title":"Voyager Receives FDA Ind Clearance for Vy1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640995912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640995912?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUABDQ4DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959220","title":"Voyager Therapeutics - to Initiate Vy1706 Clinical Trial in Adults With Early Alzheimer's; Dosing Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959220?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUABDQ4DX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064580","title":"Voyager Therapeutics’ Amy Quinlan, principal accounting officer, files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064580","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636064580?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:02","pubTimestamp":1779134520,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Principal Accounting Officer Amy Quinlan filed an initial ownership statement reporting 36,749 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbxSBfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636076306","title":"Analysts’ Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636076306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636076306?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:00","pubTimestamp":1779109252,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monopar Therapeutics Inc (MNPR), Voyager Therapeutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-monopar-therapeutics-inc-mnpr-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-monopar-therapeutics-inc-mnpr-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4585","BK4139","MNPR","BK4581","LABU","HCSG","BK4137","BK4588","LU0128526141.USD","XLV","VYGR","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635441117","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635441117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635441117?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:50","pubTimestamp":1778777405,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR) and Climb Bio (CLYM) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","XBI","BK4139","BK4581","LABU","HCSG","BK4137","BK4588","LU0128526141.USD","CLYM","VYGR","LU0029874061.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200210","title":"Voyager Asgct Late Breaker: Single Iv Dose of Vy1706 Well Tolerated, Reduced Tau in 3-Month Glp Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200210?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:01","pubTimestamp":1778666460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUAJSPSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285233","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285233?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:30","pubTimestamp":1778499051,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pelthos Therapeutics (PTHS), Voyager Therapeutics (V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-159?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-159?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTHS","BK4112","BLSX","LABU","BK4585","LU0029874061.USD","BK4581","BK4588","LU0128526141.USD","BLSG","VYGR","XBI","BK4139","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285288","title":"Canaccord Genuity Remains a Buy on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285288?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:30","pubTimestamp":1778499040,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Voyager Therapeutics, with a price target of $12.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634749447","title":"Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2634749447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634749447?lang=en_us&edition=fundamental","pubTime":"2026-05-09 14:01","pubTimestamp":1778306515,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Regulation category. Voyager Therapeutics Inc. is exposed to a broad array of ris...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-warns-of-broad-risk-exposure-and-uncertain-outlook-in-latest-sec-filings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voyager-therapeutics-warns-of-broad-risk-exposure-and-uncertain-outlook-in-latest-sec-filings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634469670","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Voyager Therapeutics (VYGR), Alpha Teknova (TKNO) and RxSight (RXST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634469670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634469670?lang=en_us&edition=fundamental","pubTime":"2026-05-09 02:31","pubTimestamp":1778265114,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR), Alpha Teknova (TKNO) and RxSight (RX...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-voyager-therapeutics-vygr-alpha-teknova-tkno-and-rxsight-rxst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-voyager-therapeutics-vygr-alpha-teknova-tkno-and-rxsight-rxst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4588","VYGR","BK4121","BK4137","HCSG","TKNO","XBI","LABU","BK4585","BK4198","XLV","RXST","LU0128526141.USD","BK4581","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945180","title":"Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945180?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:01","pubTimestamp":1778245315,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst maintained a Buy rating on Voyager Therapeutics today and set a price target of $18.00. Currently, the analyst consensus on Voy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oppenheimer-sticks-to-their-buy-rating-for-voyager-therapeutics-vygr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633483773","title":"Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633483773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633483773?lang=en_us&edition=fundamental","pubTime":"2026-05-08 12:07","pubTimestamp":1778213236,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on April 29. Phil Nadeau has given his Buy rati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-voyager-therapeutics-as-strong-cash-runway-and-advancing-neurology-pipeline-set-up-multiple-2026-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-voyager-therapeutics-as-strong-cash-runway-and-advancing-neurology-pipeline-set-up-multiple-2026-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633610868","title":"Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633610868","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633610868?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:41","pubTimestamp":1778190073,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $2.59M, consensus $8.79M. “As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-part...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q1-eps-47c-consensus-53c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-reports-q1-eps-47c-consensus-53c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174962","title":"Voyager Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174962?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:30","pubTimestamp":1778185813,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryVoyager Therapeutics Inc VYGR.OQ reported a quarterly adjusted loss of 47 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K34S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117962","title":"Voyager Q1 net loss narrows to $27.9 million; revenue drops to $2.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117962?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:07","pubTimestamp":1778184438,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics posted a net loss of $27.9 million, narrowing from $31 million, as revenue fell 59.9% to $2.6 million.Research and development expense dropped 21.9% to $24.6 million, while general and administrative costs declined 13.5% to $8.3 million.Cash, cash equivalents and marketable securities ended at $171.7 million, with runway expected into 2028.VY1706 and NBIB-'233 completed IND-enabling GLP toxicology, with first-in-human dosing for VY1706 expected in H2 2026; tau PET imaging efficacy data for VY7523 expected in H2 2026.CEO Alfred W. Sandrock Jr. said Voyager expects third-party data in mid-2026 that could help confirm tau knockdown as an approach in Alzheimer’s disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLDGbTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","VYGR","BK4112","LU2095319765.USD","NDAQ","SG9999014021.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SG9999014005.SGD","BK4588","SG9999014013.SGD","LU2210150020.SGD","LU0314104364.USD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176394","title":"BRIEF-Voyager Therapeutics Q1 Collaboration Revenue USD 2.593 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176394","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176394?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184106,"startTime":"0","endTime":"0","summary":"BRIEF-Voyager Therapeutics Q1 Collaboration Revenue USD 2.593 Million\n\n\nMay 07 (Reuters) - Voyager Therapeutics Q1 net income USD -27.937 million.\n\nQ1 basic EPS USD -0.47\nQ1 operating income USD -30.27 million\nQ1 pretax profit USD -27.923 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLXFB19D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1108},{"period":"1month","weight":-0.1679},{"period":"3month","weight":-0.326},{"period":"6month","weight":-0.2376},{"period":"1year","weight":-0.048},{"period":"ytd","weight":-0.1425}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.004281},{"month":2,"riseRate":0.545455,"avgChangeRate":0.057874},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037898},{"month":4,"riseRate":0.454545,"avgChangeRate":0.014405},{"month":5,"riseRate":0.636364,"avgChangeRate":0.040925},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.002273},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019026},{"month":8,"riseRate":0.6,"avgChangeRate":-0.020662},{"month":9,"riseRate":0.2,"avgChangeRate":0.071458},{"month":10,"riseRate":0.3,"avgChangeRate":-0.010359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.07862},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.036226}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction